Johnson & Johnson (JNJ)vsLantheus Holdings Inc (LNTH)
JNJ
Johnson & Johnson
$265.58
-0.29%
HEALTHCARE · Cap: $640.02B
LNTH
Lantheus Holdings Inc
$100.25
-0.14%
HEALTHCARE · Cap: $6.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 6192% more annual revenue ($97.93B vs $1.56B). JNJ leads profitability with a 21.5% profit margin vs 17.7%. LNTH appears more attractively valued with a PEG of 0.61. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
LNTH
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.9%
Fair Value
$140.57
Current Price
$265.58
$125.01 premium
Margin of Safety
-1.3%
Fair Value
$66.41
Current Price
$100.25
$33.84 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Every $100 of equity generates 23 in profit
Growing faster than its price suggests
Strong operational efficiency at 25.8%
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 0.9%
2.7% revenue growth
Weak financial health signals
Earnings declined 0.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : LNTH
The strongest argument for LNTH centers on Return on Equity, PEG Ratio, Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 25.8%. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : LNTH
The primary concerns for LNTH are Revenue Growth, Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
JNJ profiles as a mature stock while LNTH is a value play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.23 — expect wider price swings.
JNJ is growing revenue faster at 6.6% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 57/100), backed by strong 21.5% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Lantheus Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Lantheus Holdings, Inc. develops, manufactures and markets diagnostic and therapeutic agents and products that assist physicians in the diagnosis and treatment of heart, cancer and other diseases worldwide. The company is headquartered in North Billerica, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?